With two completed Phase 3 trials, the consistency of retatrutide's results across different populations is striking and exactly what the FDA looks for
Can you reconstitute peptides with acetic acid
For instance, Kaiser Permanente plans to revise its coverage criteria starting January 1, 2025, leading to inquiries about whether Kaiser covers weight loss drugs, as it will exclude coverage for GLP-1 medications when prescribed exclusively for reducing body mass in patients with a BMI under 40
Products offered online or through unverified channels are likely to be unauthorised or counterfeit, and their use is unsafe
Obesity Phase 2 trials showed 22.8-24.2% body-weight change at 8-12mg doses over 48 weeks, comparable to bariatric surgery
The cardiovascular risk profile of the average participant at week 24 looks meaningfully better than it did at week zero, independent of the weight loss itself